Back to search results

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Huntsman Cancer Institute, Salt Lake City, Utah, United States

    Contact: Study coordinator (Kaitlin Stephens) · Kaitlin.Stephens@hci.utah.edu · 801-213-8494
    Contact: Principal Investigator (Siwen Hu-Lieskovan, PhD, MD)
Study leads

  • Siwen Hu-Lieskovan, PhD, MD

    Principal Investigator

    Huntsman Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)